retatrutide type 2 diabetes trial results 2024 phase 2 ada demonstrate benefits of in obesity, diabetes, NASH Efficacy and Safety of Retatrutide – 🚨Breaking: Retatrutide's first Phase 3

this was particularly evident for patients treated with once-weekly GLP-1 RAs at 12 months post-index, where a mean weight loss of 2.8 kg (95% CI 3.6, 2.1) was reported for adherent patients, whereas poor adherence was associated with a weight gain of 0.2 kg ( 0.5, 0.9) (Supplemental Fig

Among 113,207 new users of SGLT2 inhibitors, the cumulative incidence of treatment discontinuation was 27.9% at 1 year and 45.9% at 3 years, with a cumulative incidence of reinitiation of 40.4% at 1 year and 55.7% at 3 years after discontinuation

doi: 10.1016/j.amjcard.2012.01.379

Some research shows that glutathione may even help prevent the progression of cancer

Oxidative stress and neurodegeneration: where are we now